#Japan #IVF #Kawagoe #EXORPHIA #Oocyte Society

Exciting Research Presentation by EXORPHIA

EXORPHIA, a pioneering company in the field of reproductive medicine, is set to present at the 67th Japanese Oocyte Society Meeting, taking place on June 6th and 7th, 2026, at the Westa Kawagoe in Kawagoe City, Saitama Prefecture. This annual event is renowned for bringing together experts to discuss significant advances in oocyte, embryo, and assisted reproductive technologies (ART).

The theme for this year's conference is "Fertility - Hope for the Future," inviting a wide range of discussions on the latest knowledge and innovations aimed at advancing reproductive medicine.

Presentation Details

• - Presentation ID: O-042
• - Title: "Improving IVF Embryo Quality through Dynamics Regulation of MSC-Derived EVs Using a Novel Video Analysis Method"
• - Date and Time: June 6, 2026, from 10:10 AM to 11:10 AM
• - Session: General Oral Presentation on Primary Ovarian Insufficiency (Clinical)
• - Venue: Westa Kawagoe, Hall 3
• - Presenter: Izumi Kaneko, Head of Drug Discovery Research at EXORPHIA

In this presentation, EXORPHIA will report on their innovative research focused on using extracellular vesicles (EVs) derived from umbilical Mesenchymal Stem Cells (MSCs) in embryo culture. By employing a unique video analysis method, the research aims to elucidate the regulatory mechanisms of embryo dynamics and its consequent effects on improving IVF embryo quality.

The study specifically investigates the impact of EVs on the embryonic development timeline, seeking to uncover mechanisms that have previously remained unobservable.

Implications for Fertility Treatments

As ovarian function and the quality of oocytes and embryos are heavily influenced by age, the outcomes of ART can significantly vary, posing physical, mental, and economic strains on patients.

The research being presented holds promise in providing a groundbreaking approach to enhance embryo culture environments. It targets cases where diminished embryo development capacity is associated with aging or decreased ovarian reserve. This new approach may lead to improved outcomes in in vitro fertilization (IVF) treatments and potentially reduce the number of required treatment cycles.

About EXORPHIA

• - Company Name: EXORPHIA
• - Location: 6th Floor, Otemachi Building, 1-6-1 Otemachi, Chiyoda-ku, Tokyo, Japan
• - CEO: Koji Kuchiishi
• - Founded: 2019
• - Website: www.exorphia.com

Contact Information

For inquiries, please reach out to EXORPHIA's Public Relations:

• - Email: [email protected]
• - Phone: 03-6824-0550

We look forward to sharing our findings that aim to provide hope and improvement for future fertility treatments.